Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib and Afatinib in Advanced Refractory Solid Tumors
NCT06302621Phase 1Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of pemigatinib and afatinib in solid tumor and cholangiocarcinoma (CCA) (3 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Maximum Tolerated Dose at 21 days and Objective Response Rate up to 1 year. Started Apr 2024; status: recruiting.
02
Drugs
pemigatinibafatinib
03
Conditions
solid tumorcholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06302621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06302621.